Guidance for the prevention and treatment of cancer-associated venous thromboembolism

被引:147
|
作者
Khorana, Alok A. [1 ,2 ]
Carrier, Marc [3 ]
Garcia, David A. [4 ]
Lee, Agnes Y. Y. [5 ,6 ]
机构
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA
[2] Cleveland Clin, Case Comprehens Canc Ctr, Cleveland, OH 44195 USA
[3] Univ Ottawa, Dept Med, Ottawa Hosp Res Inst, Ottawa, ON, Canada
[4] Univ Washington, Div Hematol, Sch Med, Seattle, WA 98195 USA
[5] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[6] Vancouver Coastal Hlth Author, Vancouver, BC, Canada
关键词
Venous thromboembolism; Prevention; Risk factors; Cancer; Direct oral anticoagulants (DOAC); New oral anticoagulants (NOAC); PATIENTS RECEIVING CHEMOTHERAPY; MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; RISK; EVENTS; THROMBOPROPHYLAXIS; COMPLICATIONS; TINZAPARIN; PREDICTION;
D O I
10.1007/s11239-015-1313-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Venous thromboembolism (VTE) is a highly prevalent complication of malignancy with emerging changes in incidence, diagnosis and treatment paradigms. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance based on existing guidelines and consensus expert opinion where guidelines are lacking. We address a) the appropriate workup to search for occult malignancy in patients with idiopathic VTE, b) identification of high-risk cancer patients for primary thromboprophylaxis, c) the appropriate immediate and long-term treatment for people with cancer diagnosed with acute thromboembolism, d) the appropriate duration of anticoagulation and e) the appropriate treatment strategy in patients with recurrent VTE on anticoagulation. Areas of controversy and future directions in this field are highlighted.
引用
收藏
页码:81 / 91
页数:11
相关论文
共 50 条
  • [21] Current status of treatment of cancer-associated venous thromboembolism
    Xiong, Wei
    THROMBOSIS JOURNAL, 2021, 19 (01)
  • [22] Update: Anticoagulant Treatment of Cancer-associated Venous Thromboembolism
    Riess, Hanno
    PHLEBOLOGIE, 2025, 54 (02) : 78 - 83
  • [23] Cancer-associated thrombosis: New considerations in the treatment and prevention of recurrent venous thromboembolism - Introduction
    Goodin, S
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 : S3 - S3
  • [24] Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?
    Pabinger, Ingrid
    Riedl, Julia
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, : 136 - 143
  • [25] Edoxaban for Cancer-Associated Venous Thromboembolism
    Nasser, Nicola J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01): : 94 - +
  • [26] Rivaroxaban for cancer-associated venous thromboembolism
    Liang, Bo
    Liang, Yi
    Zhao, Li-Zhi
    Zhao, Yu-Xiu
    Gu, Ning
    SCIENCE PROGRESS, 2021, 104 (02)
  • [27] Incidence of cancer-associated venous thromboembolism
    Ballardini, P.
    Zangirolami, A.
    Margutti, G.
    Manfredini, R.
    ANNALS OF ONCOLOGY, 2006, 17 : XI70 - XI71
  • [28] Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism
    Yhim, Ho-Young
    Bang, Soo-Mee
    BLOOD RESEARCH, 2014, 49 (02) : 77 - 79
  • [29] Apixaban: An Optimal Agent for the Treatment of Cancer-Associated Venous Thromboembolism?
    Grilusova, Kristina
    Bolek, Tomas
    Skornova, Ingrid
    Stanciakova, Lucia
    Mikusova, Veronika
    Kubisz, Peter
    Galajda, Peter
    Stasko, Jan
    Samos, Matej
    Mokan, Marian
    AMERICAN JOURNAL OF THERAPEUTICS, 2022, 29 (02) : E212 - E218
  • [30] New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism
    den Exter, Paul L.
    Kooiman, Judith
    van der Hulle, Tom
    Huisman, Menno V.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (02) : 163 - 169